Download MendeleyA General Strategy for Targeting Drugs to Bone.
Jahnke, W., Bold, G., Marzinzik, A.L., Ofner, S., Pelle, X., Cotesta, S., Bourgier, E., Lehmann, S., Henry, C., Hemmig, R., Stauffer, F., Hartwieg, J.C., Green, J.R., Rondeau, J.M.(2015) Angew Chem Int Ed Engl 54: 14575-14579
- PubMed: 26457482
- DOI: https://doi.org/10.1002/anie.201507064
- Primary Citation of Related Structures:
5DGM, 5DGS - PubMed Abstract:
Targeting drugs to their desired site of action can increase their safety and efficacy. Bisphosphonates are prototypical examples of drugs targeted to bone. However, bisphosphonate bone affinity is often considered too strong and cannot be significantly modulated without losing activity on the enzymatic target, farnesyl pyrophosphate synthase (FPPS). Furthermore, bisphosphonate bone affinity comes at the expense of very low and variable oral bioavailability. FPPS inhibitors were developed with a monophosphonate as a bone-affinity tag that confers moderate affinity to bone, which can furthermore be tuned to the desired level, and the relationship between structure and bone affinity was evaluated by using an NMR-based bone-binding assay. The concept of targeting drugs to bone with moderate affinity, while retaining oral bioavailability, has broad application to a variety of other bone-targeted drugs.
Organizational Affiliation:
Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland). wolfgang.jahnke@novartis.com.
